JP2019535651A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535651A5 JP2019535651A5 JP2019517873A JP2019517873A JP2019535651A5 JP 2019535651 A5 JP2019535651 A5 JP 2019535651A5 JP 2019517873 A JP2019517873 A JP 2019517873A JP 2019517873 A JP2019517873 A JP 2019517873A JP 2019535651 A5 JP2019535651 A5 JP 2019535651A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- patient
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403786P | 2016-10-04 | 2016-10-04 | |
| US62/403,786 | 2016-10-04 | ||
| PCT/US2017/055055 WO2018067646A1 (en) | 2016-10-04 | 2017-10-04 | Compounds and methods for activating tie2 signaling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535651A JP2019535651A (ja) | 2019-12-12 |
| JP2019535651A5 true JP2019535651A5 (cg-RX-API-DMAC7.html) | 2020-11-19 |
Family
ID=61832135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517873A Pending JP2019535651A (ja) | 2016-10-04 | 2017-10-04 | Ｔｉｅ２シグナル伝達を活性化するための化合物及び方法 |
Country Status (14)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| AU2018266690A1 (en) * | 2017-05-08 | 2019-12-12 | Asclepix Therapeutics, Inc. | Biodegradable microparticles for sustained delivery of anti-angiogenic peptide |
| EP3661536A4 (en) | 2017-08-03 | 2021-07-21 | Asclepix Therapeutics, Inc. | PROCESSES FOR IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE THE TIE2 RECEPTOR |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF |
| KR20210146352A (ko) * | 2019-03-26 | 2021-12-03 | 아스클리픽스 테라퓨틱스, 인크. | 안구 질환 치료용 조성물 및 방법 |
| CN117126233A (zh) * | 2022-05-20 | 2023-11-28 | 杭州禾泰健宇生物科技有限公司 | 一种类肽化合物及其应用 |
| WO2024044745A2 (en) * | 2022-08-26 | 2024-02-29 | Asclepix Therapeutics, Inc. | Formulations for intraocular delivery of peptides derived from type iv collagen |
| KR20240133892A (ko) * | 2023-02-28 | 2024-09-05 | 주식회사 파멥신 | 전신 모세혈관 누출 증후군의 예방 또는 치료용 조성물 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU663053B2 (en) | 1990-06-11 | 1995-09-28 | Gilead Sciences, Inc. | Nucleic acid ligands |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| EP1405911A1 (en) | 1994-07-20 | 2004-04-07 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| ATE320486T1 (de) | 1999-05-05 | 2006-04-15 | Phylogica Ltd | Isolierung von biologischen modulatoren aus bibiotheken mit biologisch vielfältigen genfragmenten |
| AU4761100A (en) | 1999-05-26 | 2000-12-18 | Kalle Saksela | Methods and materials for generating sh3 domains with tailored binding properties |
| SE0001877D0 (sv) | 2000-05-22 | 2000-05-22 | Klaus Mosbach | Molecular imprinting |
| ES2335861T3 (es) | 2000-09-08 | 2010-04-06 | Universitat Zurich | Grupos de proteinas repetitivas que comprenden modulos repetitivos. |
| DE10053224A1 (de) | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
| EP2284270A3 (en) | 2000-12-13 | 2012-07-25 | Anaphore, Inc. | Method for the identification and isolation of binding polypeptides from combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains |
| MXPA04001804A (es) | 2001-08-30 | 2005-03-07 | Biorexis Pharmaceutical Corp | Proteinas de fusion de transferrina modificada. |
| AU2003282724B2 (en) | 2002-10-02 | 2010-03-04 | Catalyst Biosciences, Inc. | Methods of generating and screening for proteases with altered specificity |
| PT1587907E (pt) | 2003-01-07 | 2011-04-08 | Dyax Corp | Biblioteca de domínios de kunitz |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
| WO2007033215A2 (en) * | 2005-09-12 | 2007-03-22 | The Johns Hopkins University | Compositions having antiangiogenic activity and uses thereof |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| KR101580937B1 (ko) | 2007-06-01 | 2015-12-31 | 유니버시티 오브 매릴랜드, 발티모어 | 면역글로불린 불변영역 Ｆｃ 수용체 결합제 |
| AR070032A1 (es) * | 2007-11-09 | 2010-03-10 | Genentech Inc | Composiciones y metodos de uso de antagonistas quinasa-1 similar al receptor de la activina (alk-1) |
| US9051349B2 (en) | 2007-11-21 | 2015-06-09 | Alba Therapeutics Corporation | Larazotide acetate compositions |
| CN103495170A (zh) * | 2009-07-07 | 2014-01-08 | 诺尔姆奥克西斯公司 | 使用肌醇三焦磷酸减少多药抗性的方法 |
| EP2649095B1 (en) | 2010-12-10 | 2021-10-06 | Aleksander S. Popel | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
| EP2788473A4 (en) | 2011-12-09 | 2015-11-11 | Univ Johns Hopkins | ARTIFICIAL ANTIGEN PRESENTING CELLS WITH DEFINED AND DYNAMIC FORM |
| CA2914764C (en) | 2013-06-07 | 2021-10-26 | The Johns Hopkins University | A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis-and lymphangiogenesis-dependent diseases |
-
2017
- 2017-10-04 SG SG10202103032QA patent/SG10202103032QA/en unknown
- 2017-10-04 AU AU2017339970A patent/AU2017339970A1/en not_active Abandoned
- 2017-10-04 CN CN201780074408.5A patent/CN110177563A/zh active Pending
- 2017-10-04 MX MX2019003895A patent/MX2019003895A/es unknown
- 2017-10-04 JP JP2019517873A patent/JP2019535651A/ja active Pending
- 2017-10-04 EA EA201990868A patent/EA201990868A1/ru unknown
- 2017-10-04 WO PCT/US2017/055055 patent/WO2018067646A1/en not_active Ceased
- 2017-10-04 US US16/336,777 patent/US20190225670A1/en not_active Abandoned
- 2017-10-04 EP EP17859077.4A patent/EP3522906B1/en active Active
- 2017-10-04 BR BR112019006735A patent/BR112019006735A2/pt not_active Application Discontinuation
- 2017-10-04 KR KR1020197012909A patent/KR20190066040A/ko not_active Ceased
- 2017-10-04 CA CA3038809A patent/CA3038809A1/en not_active Abandoned
-
2019
- 2019-03-28 IL IL265694A patent/IL265694A/en unknown
- 2019-04-12 ZA ZA2019/02344A patent/ZA201902344B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535651A5 (cg-RX-API-DMAC7.html) | ||
| HRP20201842T1 (hr) | Liječenje amd korištenjem aav2 varijante s afliberceptom | |
| JP2017533201A5 (cg-RX-API-DMAC7.html) | ||
| JP2016065094A5 (cg-RX-API-DMAC7.html) | ||
| JP2019194251A5 (cg-RX-API-DMAC7.html) | ||
| RU2018142768A (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| JP2016516073A5 (cg-RX-API-DMAC7.html) | ||
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| JP2016528202A5 (cg-RX-API-DMAC7.html) | ||
| MX383971B (es) | Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan. | |
| NZ595063A (en) | Polypeptides from neisseria meningitidis | |
| JP2015517488A5 (cg-RX-API-DMAC7.html) | ||
| JP2016509011A5 (cg-RX-API-DMAC7.html) | ||
| JP2016521712A5 (cg-RX-API-DMAC7.html) | ||
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| JP2010202664A5 (cg-RX-API-DMAC7.html) | ||
| JP2019203035A5 (cg-RX-API-DMAC7.html) | ||
| JP2018509388A5 (cg-RX-API-DMAC7.html) | ||
| JP2018505882A5 (cg-RX-API-DMAC7.html) | ||
| JP2017503014A5 (cg-RX-API-DMAC7.html) | ||
| JP2020518651A5 (cg-RX-API-DMAC7.html) | ||
| JP2016517421A5 (cg-RX-API-DMAC7.html) | ||
| JP2020518287A5 (cg-RX-API-DMAC7.html) | ||
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| JP2018530574A5 (cg-RX-API-DMAC7.html) |